New nucleoside analogues for chronic hepatitis B.

Abstract

In recent years, an in vitro system for screening nucleoside analogues against hepatitis B virus has yielded several compounds with a high therapeutic index. Phase I and II studies have also shown a potent in vivo antiviral effect of fialuridine and lamivudine in patients with chronic hepatitis B. The use of fialuridine was associated with unexpectedly severe mitochondrial dysfunction; in contrast, lamivudine had virtually no side-effects. Experience in liver transplant patients with recurrent hepatitis B shows that famciclovir may be another effective antivirotic drug with good tolerance.

• Authors: S W Schalm, R A de Man, R A Heijtink, H G Niesters
• Journal: Journal of hepatology (J Hepatol) Vol. 22 Issue 1 Suppl Pg. 52-6 ( 1995) ISSN: 0168-8278 [Print] Netherlands
• PMID: 7602078 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antiviral Agents
• Nucleosides
• Lamivudine
• Arabinofuranosyluracil
• 2-Aminopurine
• fialuridine
• Zalcitabine
• Famciclovir

Topics

• 2-Aminopurine (analogs & derivatives, therapeutic use)
• Antiviral Agents (therapeutic use)
• Arabinofuranosyluracil (analogs & derivatives, therapeutic use)
• Chronic Disease
• Drug Evaluation, Preclinical
• Famciclovir
• Hepatitis B (drug therapy)
• Humans
• Lamivudine
• Nucleosides (therapeutic use)
• Zalcitabine (analogs & derivatives, therapeutic use)